Clinical response and miR-29b predictive significance in older AML patients treated with a 10-day schedule of decitabine.

@article{Blum2010ClinicalRA,
  title={Clinical response and miR-29b predictive significance in older AML patients treated with a 10-day schedule of decitabine.},
  author={William G Blum and Ramiro Garzon and Rebecca B. Klisovic and Sebastian Schwind and Alison Tara Walker and Susan Geyer and Shujun Liu and Violaine Havelange and Heiko Becker and Larry J. Schaaf and Jon Mickle and Hollie Devine and Cheryl A Kefauver and Steven Michael Devine and Kenneth K Y Chan and Nyla A. Heerema and Clara D. Bloomfield and Michael R Grever and John C. Byrd and Miguel Angel Villalona-Calero and Carlo M. Croce and Guido Marcucci},
  journal={Proceedings of the National Academy of Sciences of the United States of America},
  year={2010},
  volume={107 16},
  pages={7473-8}
}
A phase II clinical trial with single-agent decitabine was conducted in older patients (>or=60 years) with previously untreated acute myeloid leukemia (AML) who were not candidates for or who refused intensive chemotherapy. Subjects received low-dose decitabine at 20 mg/m(2) i.v. over 1 h on days 1 to 10. Fifty-three subjects enrolled with a median age of 74 years (range, 60-85). Nineteen (36%) had antecedent hematologic disorder or therapy-related AML; 16 had complex karyotypes (>or=3… CONTINUE READING
Related Discussions
This paper has been referenced on Twitter 4 times. VIEW TWEETS

Citations

Publications citing this paper.
Showing 1-10 of 175 extracted citations

Treatment of Low-Blast Count AML using Hypomethylating Agents

Mediterranean journal of hematology and infectious diseases • 2017
View 10 Excerpts
Highly Influenced

DNMT3A mutations in acute myeloid leukemia.

The New England journal of medicine • 2010
View 5 Excerpts
Highly Influenced

A comparison of toxicities in acute myeloid leukemia patients with and without renal impairment treated with decitabine.

Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners • 2018
View 1 Excerpt

Similar Papers

Loading similar papers…